LXRX Q3 2018 Earnings — Lexicon Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

LXRXLexicon Pharmaceuticals, Inc.

$693M

Q3 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$7M-74.6% YoY

Gross Profit

$6M92.0% margin

Operating Income

-$23M-336.1% margin

Net Income

-$28M-401.3% margin

EPS (Diluted)

$-0.26

QoQ Revenue Growth

-50.1%

Cash Flow

Operating Cash Flow

-$22M

Free Cash Flow

-$22M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$310M

Total Liabilities

$340M

Stockholders' Equity

-$29M

Cash & Equivalents

$49M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$7M	$27M	-74.6%
Gross Profit	$6M	$26M	-76.1%
Operating Income	-$23M	-$30M	+21.9%
Net Income	-$28M	-$31M	+10.4%